Pituitary adenylyl cyclase-activating polypeptide is an intrinsic regulator of Treg abundance and protects against experimental autoimmune encephalomyelitis.
about
The neuropeptide vasoactive intestinal peptide: direct effects on immune cells and involvement in inflammatory and autoimmune diseasesPituitary adenylate cyclase-activating polypeptide ameliorates experimental acute ileitis and extra-intestinal sequelaePeripheral blood immune cell methylation profiles are associated with nonhematopoietic cancersPACAP deficiency sensitizes nigrostriatal dopaminergic neurons to paraquat-induced damage and modulates central and peripheral inflammatory activation in micePACAP interacts with PAC1 receptors to induce tissue plasminogen activator (tPA) expression and activity in schwann cell-like culturesEffects of combinatorial treatment with pituitary adenylate cyclase activating peptide and human mesenchymal stem cells on spinal cord tissue repair.Vasoactive intestinal peptide: a neuropeptide with pleiotropic immune functions.Vasoactive intestinal peptide loss leads to impaired CNS parenchymal T-cell infiltration and resistance to experimental autoimmune encephalomyelitis.Vulnerability imposed by diet and brain trauma for anxiety-like phenotype: implications for post-traumatic stress disorders.Pituitary adenylate cyclase activating peptide deficient mice exhibit impaired thymic and extrathymic regulatory T cell proliferation during EAEVPAC2 (vasoactive intestinal peptide receptor type 2) receptor deficient mice develop exacerbated experimental autoimmune encephalomyelitis with increased Th1/Th17 and reduced Th2/Treg responses.VIP and PACAP: recent insights into their functions/roles in physiology and disease from molecular and genetic studies.Differential regulatory role of pituitary adenylate cyclase-activating polypeptide in the serum-transfer arthritis model.Comparative protein composition of the brains of PACAP-deficient mice using mass spectrometry-based proteomic analysis.Human mesenchymal stem/stromal cells suppress spinal inflammation in mice with contribution of pituitary adenylate cyclase-activating polypeptide (PACAP).Targeting VIP and PACAP receptor signalling: new therapeutic strategies in multiple sclerosis.VIP Regulates the Development & Proliferation of Treg in vivo in spleenInvolvement of calcitonin gene-related peptide and receptor component protein in experimental autoimmune encephalomyelitis.Signaling through the neuropeptide GPCR PAC₁ induces neuritogenesis via a single linear cAMP- and ERK-dependent pathway using a novel cAMP sensor.Pharmacology and functions of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: IUPHAR review 1.Neuropeptides: keeping the balance between pathogen immunity and immune toleranceNeuropeptide PACAP in mouse liver ischemia and reperfusion injury: immunomodulation by the cAMP-PKA pathwayVIP and PACAP: neuropeptide modulators of CNS inflammation, injury, and repairPituitary adenylate cyclase-activating polypeptide expression in peripheral blood mononuclear cells of migraineurs.VPAC1 receptor (Vipr1)-deficient mice exhibit ameliorated experimental autoimmune encephalomyelitis, with specific deficits in the effector stage.G protein-coupled receptors as therapeutic targets for multiple sclerosis.Neuropeptide receptors as potential drug targets in the treatment of inflammatory conditionsPACAP signaling exerts opposing effects on neuroprotection and neuroinflammation during disease progression in the SOD1(G93A) mouse model of amyotrophic lateral sclerosisNeuropeptides as pleiotropic modulators of the immune response.PACAP is an endogenous protective factor-insights from PACAP-deficient mice.mTOR kinase, a key player in the regulation of glial functions: relevance for the therapy of multiple sclerosis.Pituitary adenylate cyclase-activating polypeptide (PACAP) contributes to the proliferation of hematopoietic progenitor cells in murine bone marrow via PACAP-specific receptor.Influence of terminal differentiation and PACAP on the cytokine, chemokine, and growth factor secretion of mammary epithelial cells.Inhaled vasoactive intestinal peptide exerts immunoregulatory effects in sarcoidosis.Pituitary adenylate cyclase-activating polypeptide attenuates tumor necrosis factor-α-induced apoptosis in endothelial colony-forming cells.The importance of the nurse cells and regulatory cells in the control of T lymphocyte responses.PACAP38 suppresses cortical damage in mice with traumatic brain injury by enhancing antioxidant activity.Pituitary adenylate cyclase-activating polypeptide (PACAP) protects against mitoxantrone-induced cardiac injury in mice.Comparative examination of inner ear in wild type and pituitary adenylate cyclase activating polypeptide (PACAP)-deficient mice.Modulation of Immune Checkpoints and Graft-versus-Leukemia in Allogeneic Transplants by Antagonizing Vasoactive Intestinal Peptide Signaling.
P2860
Q26851670-490B9752-FEBA-4043-B508-43929B67B405Q27345033-ADBF1D9D-CE34-4F3C-95D4-74937A264EECQ28387330-B0B64531-5C55-4A2B-9765-A86580C3DBB1Q28397422-67272D18-903E-4675-8013-1FCE548D6B07Q28543252-EBF12652-F768-4D18-AEAE-77EE21590ACAQ33781107-F33B23D0-E8D8-4D9B-9461-F3757AABDC5AQ34238010-4E30E0A2-ECB3-412A-9AFB-78792EE70328Q34320335-3647BBD6-83AE-47E5-B8AD-9799957D0B34Q34618475-2088E59C-1554-4955-9F0B-7ABEDA48BB32Q34684150-F35A086C-4FA8-40DC-8CB5-C5104CA7530CQ34765538-A31B8368-E2A7-4118-8565-5EDF16E894BAQ34788079-92DDA247-596E-472E-B91A-D8A6BC6CBFD6Q35061170-1A640A8C-614D-49E8-B001-FE21555C8145Q35124417-ED299C6C-DE79-43E5-9F64-D745E653E757Q35136492-7F7446B0-058E-4B48-9536-E5FABAF0FBB2Q35295564-7ED5E893-FE6E-4D00-9467-D1A4E081B7F5Q35777156-5FB3F6AD-6AE2-4F93-A03B-9E1E5C625950Q35799802-5B6FFC71-9B3F-4201-A3F8-A6644CE5942AQ36117474-920D862B-9BA7-438D-BD3E-2CFBBF6B30D0Q36153216-FFFC8CC3-F8EF-4D2E-9F11-63A74E95FD79Q36158715-8E5B4221-ADB7-40EC-9A17-57D9E02A6E55Q36342098-84B28E33-9F98-49C4-8220-4C83689785B9Q36929423-170EE79D-E763-4DFB-AC95-E86200DF310DQ36994462-7009ED24-E177-4A52-8236-C2E320E23D84Q37054934-4DB5DC82-7A7A-41C9-9EF6-8805533A9D63Q37112554-C1169036-AAC2-4D1E-9E16-6BBA4E3A7DB6Q37492012-21135AC7-3F80-4CB8-A21D-856CC54DB047Q37640081-C238C391-7B01-44B3-96EF-85139070F941Q37898396-303581A3-A6DC-4C90-A224-2CF958B48292Q38005003-A2D0ED6F-DE8A-42AD-B915-AC59F36AEFBFQ38050335-B04CC726-5ECE-4C3B-997C-781C89B4EEA2Q38694548-93102795-3766-4BD5-8ACE-6AC99C371084Q39045021-CD474FC7-8D87-4F4B-92B9-840B3148B9B2Q39876461-2050FCE8-28BF-44BD-84F9-2E41E60448C5Q40992476-35B166D6-FBEF-4027-88A6-0FD094F7CAC2Q43233982-96340D03-A497-43CE-A2D2-15CD2AE0B99DQ46882701-DAFB3D9B-E7F4-4F39-8C5A-EF7B28A703A0Q47694093-A08A3C23-BB0F-456B-AC44-A40CC51226DBQ48744942-08FEC667-5FF0-4A6D-B7C0-5C199E5EE814Q51450182-9B4C37BC-BCD8-47DC-B5AA-FCB80AB009FC
P2860
Pituitary adenylyl cyclase-activating polypeptide is an intrinsic regulator of Treg abundance and protects against experimental autoimmune encephalomyelitis.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 03 February 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Pituitary adenylyl cyclase-act ...... autoimmune encephalomyelitis.
@en
Pituitary adenylyl cyclase-act ...... autoimmune encephalomyelitis.
@nl
type
label
Pituitary adenylyl cyclase-act ...... autoimmune encephalomyelitis.
@en
Pituitary adenylyl cyclase-act ...... autoimmune encephalomyelitis.
@nl
prefLabel
Pituitary adenylyl cyclase-act ...... autoimmune encephalomyelitis.
@en
Pituitary adenylyl cyclase-act ...... autoimmune encephalomyelitis.
@nl
P2093
P2860
P356
P1476
Pituitary adenylyl cyclase-act ...... autoimmune encephalomyelitis.
@en
P2093
Catalina Abad
Hongmei Dong
James A Waschek
Javier Leceta
Robert Lopez
Rosa P Gomariz
Yossan-Var Tan
P2860
P304
P356
10.1073/PNAS.0812257106
P407
P577
2009-02-03T00:00:00Z